Newleos Therapeutics Secures $93.5M Series A to Advance CNS Drug Development
Key Highlights Newleos Therapeutics secures $93.5 million in Series A funding, led by Goldman Sachs Alternatives, with participation from Novo Holdings A/S,…
Browsing Tag
David Donabedian
2 posts
Solu Therapeutics Appoints Dr. Philip J. Vickers as New CEO
Solu Therapeutics, a precision-medicine company, announces the appointment of Dr. Philip J. Vickers as its new President and…